Harvest Integrated Research Organization (HiRO) announced its acquisition of Courante Oncology, a full-service clinical research organization (CRO) based in Excelsior, Minnesota. According to data captured in the LevinPro HC database, this transaction represents the 26th CRO acquisition of the year.
Courante Oncology provides clinical research consulting and services to pharmaceutical and medical device companies that are developing oncology products.
HiRO is a CRO based in Shanghai, China. With global operations and integration capabilities, it provides a range of solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory, pharmacovigilance, statistics, data management, end-to-end project management and clinical and medical monitoring services.
With the acquisition, HiRO will further its capabilities in managing global studies and extending its presence into the U.S. market. The amount of the deal was not disclosed.
